Skip to main content
SpringerLink
Log in

Normal thyroid-stimulating hormone levels, autoimmune activation, and coronary heart disease risk

Endocrine volume 48, pages 218–226 (2015)Cite this article

Abstract

Whether euthyroid status affects cardiovascular disease risk is unclear. We aimed to investigate whether serum thyroid-stimulating hormone (TSH) levels within the normal range are related to the risk of coronary heart disease (CHD). In participants of the Turkish Adult Risk Factor Study (mean age 52.7 ± 11.5), in whom TSH was measured in the 2004/05 survey, cross-sectional and longitudinal analyses were performed. Subjects with TSH concentrations <0.3 and >4.2 mIU/L were excluded to ensure euthyroid status leaving 956 individuals as the study sample. Mean follow-up was 4.81 ± 1.3 years. Men had 18 % lower (p < 0.001) geometric mean TSH levels (1.10 mIU/L) than women (1.35 mIU/L). Correlations of TSH with risk variables were notably virtually absent except weakly positive ones in men with age and systolic blood pressure (SBP). The age-adjusted TSH mid-tertile in men was associated with lowest lipoprotein [Lp](a), apoB, and total cholesterol values. Incident CHD was predicted in Cox regression analyses in men [HR of 2.45 (95 %CI 1.05; 5.74] and in combined sexes by the lowest compared with the highest TSH tertile, after adjustment for age, smoking status, SBP, and LDL-cholesterol. Analysis for combined prevalent and incident CHD stratified by metabolic syndrome (MetS) confirmed the independent association with the lowest TSH tertile in men, specifically in men without MetS. TSH levels within normal range, low due to partial assay failure, may manifest as independent predictors of incident CHD, particularly in middle-aged men. Autoimmune responses involving serum Lp(a) under oxidative stress might be implicated mechanistically.

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

USD 39.95

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Fig. 1

References

  1. J.V. Parle, P. Maisonneuve, M.C. Sheppard, P. Boyle, J.A. Franklyn, Prediction of all-cause and cardiovascular mortality in the elderly people from one low serum thyrotropin result: a 10-year cohort study. Lancet 358, 861–865 (2001)

    Article  CAS  PubMed  Google Scholar 

  2. B.O. Åsvold, T. Bjoro, T.I. Nilsen, L.J. Vatten, Association between blood pressure and serum TSH concentration within the reference range: a population-based study. J. Clin. Endocrinol. Metab. 92, 841–885 (2007)

    Article  PubMed  Google Scholar 

  3. B.O. Åsvold, L.J. Vatten, T.I. Nilsen, T. Bjøro, The association between TSH within the reference range and serum lipid concentrations in a population-based study: the HUNT Study. Eur. J. Endocrinol. 156, 181–186 (2007)

    Article  PubMed  Google Scholar 

  4. B.O. Åsvold, T. Bjøro, T.I. Nilsen, D. Gunnell, L.J. Vatten, Thyrotropin levels and risk of fatal coronary heart disease. Arch. Intern. Med. 168, 855–860 (2008)

    Article  PubMed  Google Scholar 

  5. C.H. Jung, E.J. Rhee, H.S. Shin, S.K. Jo, J.C. Won, C.Y. Park et al., Higher serum free thyroxine levels are associated with coronary artery disease. Endocr. J. 55, 819–826 (2008)

    Article  CAS  PubMed  Google Scholar 

  6. W. Huang, J. Xu, F. Jing, W.B. Chen, L. Gao, H.T. Yuan, J.J. Zhao, Functional thyrotropin receptor expression in the ventricle and the effects on ventricular BNP secretion. Endocrine Sep 26 (2013) PMID:24065308 [Epub ahead of print]

  7. D.S. McLeod, Autoimmune thyroid disease: a novel risk factor for atherosclerosis? Endocrine 44, 8–10 (2013)

    Article  CAS  PubMed  Google Scholar 

  8. O. Topaloglu, F. Gokay, K. Kucukler, F.S. Burnik, T. Mete, H.C. Yavuz et al., Is autoimmune thyroiditis a risk factor for early atherosclerosis in premenopausal women even in euthyroid status? Endocrine 44, 145–151 (2013)

    Article  CAS  PubMed  Google Scholar 

  9. A. Onat, G. Can, E. Ayhan, Z. Kaya, G. Hergenç, Impaired protection against diabetes and coronary disease by high-density lipoproteins in Turks. Metabolism 58, 1393–1399 (2009)

    Article  CAS  PubMed  Google Scholar 

  10. A. Onat, G. Hergenç, Low-grade inflammation and dysfunction of high-density lipoprotein and its apolipoproteins as a major driver of cardiometabolic risk. Metabolism 60, 499–512 (2011)

    Article  CAS  PubMed  Google Scholar 

  11. A. Onat, K. Ceyhan, Ö. Başar, B. Erer, S. Toprak, V. Sansoy, Metabolic syndrome: major impact on coronary risk in a population with low cholesterol levels—a prospective and cross-sectional evaluation. Atherosclerosis 165, 285–292 (2002)

    Article  CAS  PubMed  Google Scholar 

  12. A. Onat, G. Hergenç, S. Bulur, M. Uğur, Z. Küçükdurmaz, G. Can, The paradox of high apolipoprotein A-I levels independently predicting incident type-2 diabetes among Turks. Int. J. Cardiol. 142, 72–79 (2010)

    Article  CAS  PubMed  Google Scholar 

  13. A. Onat, G. Can, S. Murat, G. Çiçek, E. Örnek, H. Yüksel, Aggregation of lipoprotein(a) to apolipoprotein A-I underlying HDL dysfunction as a major coronary risk factor. Anadolu Kardiyol. Derg. 13, 543–551 (2013)

    CAS  PubMed  Google Scholar 

  14. A. Onat, G. Can, E. Ademoğlu, E. Çelik, A. Karagöz, E. Örnek, Coronary disease risk curve of serum creatinine is linear in Turkish men, U-shaped in women. J. Investig. Med. 61, 27–33 (2013)

    CAS  PubMed  Google Scholar 

  15. A. Onat, H. Yüksel, G. Can, B. Köroğlu, A. Kaya, S. Altay, Serum creatinine is associated with coronary disease risk even in the absence of metabolic disorders. Scand. J. Clin. Lab. Investig. 73, 569–575 (2013)

    Article  CAS  Google Scholar 

  16. A. Onat, B. Köroğlu, G. Can, A. Karagöz, E. Çelik, M. Aydın, Apparently “low” serum asymmetric dimethylarginine is associated with fasting glucose and tends toward association with type-2 diabetes. Anadolu Kardiyol. Derg. 14(1), 26–33 (2013). doi:10.5152/akd.2013.5009

    PubMed  Google Scholar 

  17. A. Onat, G. Can, Enhanced pro-inflammatory state and autoimmune activation: a breakthrough to understanding chronic diseases. Curr Pharma Design Apr 2 (2013) [Epub ahead of print]

  18. A. Onat, Risk factors and cardiovascular disease in Turkey. Atherosclerosis 156, 1–10 (2001)

    Article  CAS  PubMed  Google Scholar 

  19. S.M. Grundy, H.B. Brewer, J.I. Cleeman, S.C. Smith Jr, C. Lenfant, American Heart Association; definition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation 109, 433–438 (2004)

    Article  PubMed  Google Scholar 

  20. A. Onat, H. Uyarel, G. Hergenç, A. Karabulut, S. Albayrak, G. Can, Determinants and definition of abdominal obesity as related to risk of diabetes, metabolic syndrome and coronary disease in Turkish men: a prospective cohort study. Atherosclerosis 191, 182–190 (2007)

    Article  CAS  PubMed  Google Scholar 

  21. G.A. Rose, H. Blackburn, R.F. Gillum, R.J. Prineas, Cardiovascular Survey Methods, 2nd edn. (WHO, Geneva, 1982), pp. 124–127

    Google Scholar 

  22. B. Gencer, T.H. Colleo, V. Virgini, D.C. Bauer, J. Gussekloo, A.R. Cappola et al., Subclinical hyperthyroidism and the risk of coronary heart disease and mortality. Arch. Intern. Med. 172, 799–809 (2012)

    PubMed  Google Scholar 

  23. S. Tognini, A. Polini, G. Pasqualetti, S. Ursino, N. Caraccio, M. Ferdeghini et al., Age and gender substantially influence the relationship between thyroid status and the lipoprotein profile: results from a large cross-sectional study. Thyroid 22, 1096–1103 (2012)

    Article  CAS  PubMed  Google Scholar 

  24. M. Rotondi, P. Leporati, M.I. Rizza, A. Clerici, G. Groppelli, C. Pallavicini et al., Raised serum TSH in morbid-obese and non-obese patients: effect on the circulating lipid profile. Endocrine 43, 230–232 (2013)

    Article  Google Scholar 

  25. L. Siemińska, W. Foltyn, J. Głogowska-Szeląg, D. Kajdaniuk, B. Marek, M. Nowak et al., Relationships between adiponectin, sex hormone binding globulin and insulin resistance in hyperthyroid Graves’ disease women. Endokrynol. Pol 64, 26–29 (2013)

    PubMed  Google Scholar 

  26. C.T. Sawin, A. Geller, P.A. Wolf, A.J. Belanger, E. Baker, P. Bacharach et al., Low serum thyrotropin concentration as a risk factor for atrial fibrillation in older persons. N. Engl. J. Med. 331, 1249–1252 (1994)

    Article  CAS  PubMed  Google Scholar 

  27. J. Gussekloo, E. van Exel, A.J. de Craen, A.E. Meinders, M. Frölich, R.G. Westendorp, Thyroid status, disability and cognitive function, and survival in old age. J. Am. Med. Assoc. 292, 2591–2599 (2004)

    Article  CAS  Google Scholar 

  28. L.H. Duntas, B. Biondi, Short-term hypothyroidism after Levothyroxine-withdrawal in patients with differentiated thyroid cancer: clinical and quality of life consequences. Eur. J. Endocrinol. 156, 13–19 (2007)

    Article  CAS  PubMed  Google Scholar 

  29. A. Dardano, K.L. Ghiadoni, Y. Plantinga, N. Carraccio, A. Bemi, E. Duranti et al., Recombinant human thyrotropin reduces endothelium-dependent vasodilation in patients monitored for differentiated thyroid carcinoma. J. Clin. Endocrinol. Metab. 91, 4175–4178 (2006)

    Article  CAS  PubMed  Google Scholar 

  30. T.T. Antunes, A. Gagnon, A. Bell, A. Sorisky, Thyroid-stimulating hormone stimulates interleukin-6 release from 3T3-L1 adipocytes through a cAMP-protein kinase A pathway. Obes. Res. 13, 2066–2071 (2005)

    Article  CAS  PubMed  Google Scholar 

  31. H.C. Wang, J. Dragoo, O. Zhou, J.R. Klein, An intrinsic thyrotropin-mediated pathway of TNF-alpha production by bone marrow cells. Blood 101, 119–123 (2003)

    Article  PubMed  Google Scholar 

  32. H. Taneichi, T. Sasai, M. Ohara, H. Honma, K. Nagasawa, T. Takahashi, Higher serum free triiodothyronine levels within the normal range are associated with metabolic syndrome components in type 2 diabetic subjects with euthyroidism. Tohoku J. Exp. Med. 224, 173–178 (2011)

    Article  CAS  PubMed  Google Scholar 

  33. Q. Qi, T. Workalemahu, C. Zhang, F.B. Hu, L. Qi, Genetic variants, plasma lipoprotein(a) levels, and risk of cardiovascular mortlity and mortality among two prospective cohorts of type 2 diabetes. Eur. Heart J. 33, 325–334 (2012)

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  34. A. Onat, M. Aydın, G. Can, H.A. Çakmak, B. Köroğlu, A. Kaya et al., Impaired fasting glucose: pro-diabetic, “atheroprotective” and modified by metabolic syndrome. World. J. Diabetes 4, 210–218 (2013)

    PubMed Central  PubMed  Google Scholar 

  35. S. Mora, P.R. Kamstrup, N. Rifai, B.G. Nordestgaard, J.E. Buring, P.M. Ridker, Lipoprotein(a) and risk of type 2 diabetes. Clin. Chem. 56, 1252–1260 (2010)

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  36. A. Onat, H.A. Çakmak, G. Can, M. Yüksel, B. Köroğlu, H. Yüksel, Serum total and high-density lipoprotein phospholipids: Independent predictive value for cardiometabolic risk. Clin Nutr. Nov 1 (2013) [Epub ahead of print]

  37. K. Kocak, B. Huddam, A. Azak, L. Ortabozkoyun, M. Duranay, Coexistent findings of renal glomerular disease with Hashimoto’s thyroiditis. Clin. Endocrinol. 76, 759–762 (2012)

    Article  CAS  Google Scholar 

  38. C. Zhang, X. Li, D. Niu, R. Zi, C. Wang, A. Han et al., Increased serum levels of ß2-GPI-Lp(a) complexes and their association with premature atherosclerosis in patients with rheumatoid arthritis. Clin. Chim. Acta 412, 1332–1336 (2011)

    Article  CAS  PubMed  Google Scholar 

  39. L.R. Lopez, T.R. Bruckner, B.L. Hurley, K. Kobayashin, E. Matsuura, Determination of oxidized low-density lipoprotein (ox-LDL) versus oxLDL/beta2-GPI complexes for the assessment of autoimmune-mediated atherosclerosis. Ann. N. Y. Acad. Sci. 1109, 303–310 (2007)

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgment

We thank the Turkish Society of Cardiology and the various pharmaceutical companies (Istanbul) for financial support of the Turkish Adult Risk Factor study over the years.

Conflict of interest

None.

Author information

Authors and Affiliations

  1. Cerrahpaşa Faculty of Medicine, Nisbetiye cad. 59/24 Etiler, 34335, Istanbul, Turkey

    Altan Onat & Günay Can

  2. Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey

    Evin Ademoğlu

  3. Faculty of Medicine, Dicle University, Diyarbakır, Turkey

    Mesut Aydın

  4. Etlik Educational Hospital, Ankara, Turkey

    Etem Çelik

  5. Siyami Ersek Center for Cardiovasc Surgery, Istanbul, Turkey

    Servet Altay

  6. Giresun University, Giresun, Turkey

    Ahmet Karagöz

Authors
  1. Altan Onat
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Mesut Aydın
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Günay Can
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Etem Çelik
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Servet Altay
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Ahmet Karagöz
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Evin Ademoğlu
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Altan Onat.

Rights and permissions

Reprints and Permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Onat, A., Aydın, M., Can, G. et al. Normal thyroid-stimulating hormone levels, autoimmune activation, and coronary heart disease risk. Endocrine 48, 218–226 (2015). https://doi.org/10.1007/s12020-014-0269-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12020-014-0269-z

Keywords

search

Navigation